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Disequilibrium between bone-forming osteoblasts and
bone-resorbing osteoclasts is central to many bone dis-
eases. Here, we show that dysregulated expression of
translationally controlled isoforms of CCAAT/enhancer-
binding protein b (C/EBPb) differentially affect bone
mass. Alternative translation initiation that is controlled
by the mammalian target of rapamycin (mTOR) pathway
generates long transactivating (LAP*, LAP) and a short
repressive (LIP) isoforms from a single C/EBPb transcript.
Rapamycin, an inhibitor of mTOR signalling increases the
ratio of LAP over LIP and inhibits osteoclastogenesis in
wild type (WT) but not in C/EBPb null (c/ebpb/) or in
LIP knock-in (L/L) osteoclast precursors. C/EBPb mutant
mouse strains exhibit increased bone resorption and atte-
nuated expression of MafB, a negative regulator of osteo-
clastogenesis. Ectopic expression of LAP and LIP in
monocytes differentially affect the MafB promoter activity,
MafB gene expression and dramatically affect osteoclasto-
genesis. These data show that mTOR regulates osteoclast
formation by modulating the C/EBPb isoform ratio, which
in turn affects osteoclastogenesis by regulating MafB
expression.
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Introduction
Bone homeostasis is controlled by the interplay between
bone-forming osteoblasts and bone-resorbing osteoclasts
(Karsenty and Wagner, 2002). The dynamics of bone remo-
delling is tightly regulated (Boyle et al, 2003; Harada and
Rodan, 2003) and is based on intercellular communication
between both cell types (Martin and Sims, 2005). Disturbance
of the balance between osteoblasts and osteoclasts often
results in enhanced bone resorption, usually involving
hyperactive osteoclasts and causing focal or generalized
bone loss (Helfrich, 2003; Teitelbaum and Ross, 2003; Phan
et al, 2004; Ehrlich and Roodman, 2005).
The transcription factor CCAAT/enhancer binding protein
b (C/EBPb) is involved in the differentiation and function of
haematopoietic and mesenchymal cell types, including
macrophages and adipocytes (Screpanti et al, 1995; Tanaka
et al, 1995; Poli, 1998; Rosen and MacDougald, 2006;
Uematsu et al, 2007), cell lineages closely related to bone
cells. C/EBPb is a member of the family of C/EBP transcrip-
tion factors (a, b, g, d, e and z). C/EBPs have highly
conserved basic leucine zipper domains (bZIP) involved in
dimerization and DNA binding, and a variable N-terminal
region involved in the regulation of gene expression. C/EBPs
regulate proliferation and differentiation of many different
cell types, including adipocytes, mammary epithelial cells,
ovarian luteal cells, keratinocytes, hepatocytes, neuronal
cells, intestinal epithelial cells and cells of the haematopoietic
lineage (Ramji and Foka, 2002; Johnson, 2005; Nerlov, 2007).
The two main members, C/EBPa and b, are required for
placentogenesis (Begay et al, 2004), liver functions (Pedersen
et al, 2007; Wang et al, 2008), granulopoiesis (Zhang et al,
2002; Hirai et al, 2006) and innate immune functions (Akira
and Kishimoto, 1992; Poli, 1998). C/EBPg is ubiquitously
expressed and expression of C/EBPe is mostly confined to
granulocytes (Ramji and Foka, 2002; Johnson, 2005),
whereas C/EBPd is involved in adipogenesis and neuronal
functions (Tanaka et al, 1997; Sterneck and Johnson, 1998).
C/EBPb is an intronless gene, yet different isoforms
are expressed with successively truncated N-termini. The
C/EBPb isoforms were termed LAP*, LAP and LIP
(Descombes and Schibler, 1991) and arise by alternative
translation initiation at distinct in frame start sites
(Calkhoven et al, 2000; Xiong et al, 2001). Alternative trans-
lation initiation and thus C/EBPb isoform production is
regulated through the mammalian target of rapamycin
(mTOR) pathway: activation of mTOR enhances generation
of LIP and inhibition of mTOR enhances LAP production
(Calkhoven et al, 2000; Jundt et al, 2005). The truncated
and dominant inhibitory isoform (LIP) may also arise by
partial proteolysis of long isoforms (Sebastian and Johnson,
2006). All isoforms contain the C-terminal bZIP domain. In
addition, the long isoforms LAP* and LAP contain N-terminal
transactivation and chromatin remodelling domains. The
C/EBPb isoform ratio is thought to direct cell fate
(Kowenz-Leutz and Leutz, 1999; Calkhoven et al, 2002;
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It has been shown that over-expression of full-length
C/EBPb or of its short LIP isoform supports osteoblast differ-
entiation in vitro (Gutierrez et al, 2002; Hata et al, 2005;
Villagra et al, 2006). In agreement with this, a recent study
showed that absence of C/EBPb at embryonic and neonatal
stages results in delayed bone formation and suppression of
osteoblast differentiation (Tominaga et al, 2008). Similarly,
transgenic mice expressing only the short LIP isoform in the
osteoblast lineage displayed attenuated bone formation
(Harrison et al, 2005). Although the action of C/EBPb in
osteoblasts has been addressed in several studies, the general
function of C/EBPb in bone homeostasis, including its
potential role in osteoclasts, remains to be examined.
Here, we have used genetically altered mice, either defi-
cient for c/ebpb (/) (Sterneck et al, 1997), or expressing
only the truncated LIP isoform from its native genetic locus
(LIP knock-in; L/L), to examine C/EBPb functions in bone
tissue. Osteogenesis and osteoclastogenesis were both af-
fected in the absence of C/EBPb or in the presence of LIP
only. Importantly, the translationally controlled ratio between
LAP and LIP isoforms strongly affected osteoclastogenesis.
Rapamycin, an inhibitor of mTOR, enhanced LAP expression
and constrained differentiation of osteoclasts from wild-type
(WT, þ /þ ) mice but not from C/EBPb deficient or L/Lmice.
Expression of LAP-induced expression of MafB, a negative
regulator of osteoclast differentiation (Kim et al, 2007),
whereas LIP inhibited expression of MafB and enhanced
osteoclastogenesis. Our data suggest that signalling through
mTOR affects the C/EBPb isoform ratio that in turn regulates
MafB expression as a major factor controlling osteoclast
differentiation and bone homeostasis. Our results raise the
possibility that dysregulated translational control of C/EBPb
isoform expression might be involved in bone diseases.
Results
Expression of C/EBPb in bone cells
To examine whether C/EBPb could have a function in bone
homeostasis, expression of C/EBPb was analysed in the
different bone cell types. Immunohistochemistry of bone
tissue revealed C/EBPb protein expression in growth plate
chondrocytes (Figure 1A) and in osteoblasts (Figure 1B and
C, arrowheads), but not in osteoclasts (Figure 1B, arrow) or
osteocytes (Figure 1C, arrows). During osteoblast differentia-
tion, expression of all three C/EBPb protein isoforms in-
creased (Figure 1D). Monocytic precursors derived from the
bone marrow expressed all three C/EBPb protein isoforms
and C/EBPb expression vanished during differentiation into
osteoclasts and no C/EBPb protein was detected in mature
osteoclasts (Figure 1E). Thus, C/EBPb protein expression is
reciprocally regulated during differentiation of the two cell
lineages controlling bone homeostasis.
Affected bone mass in c/ebpb mutant mice
Reciprocal expression of C/EBPb in osteoblasts and osteo-
clasts suggested cell-type specific functions of C/EBPb and its
isoforms in bone tissue. To characterize the function of
C/EBPb and its isoforms in bone, mice expressing only the
LIP isoform from the endogenous C/EBPb locus were gener-
ated (L/L mice; Figure 2A and B) and compared with WTand
c/ebpb knock-out (/) (Sterneck et al, 1997) mice. Analysis
of liver protein extracts from 8-week-old mice confirmed
expression of the LIP isoform in L/L mice (Figure 2C). L/L
mice were born at a slightly reduced Mendelian ratio (18%,
n¼ 324). Peripheral blood cell counts, spleen and liver
weights and their histological parameters were comparable
with WT (þ /þ ) animals (data not shown). Similarly to L/L
mice, c/ebpb/ mice are born at a reduced Mendelian ratio.
However, viable mice developed normally until at least 10
weeks of age (our observation and Tanaka et al, 1995;
Sterneck et al, 1997).
Bone development was analysed by comparing L/L, c/ebpb
knock-out (/) (Sterneck et al, 1997) and WT (þ /þ ) mice
at the age of 8 weeks. C/ebpb/ animals displayed reduced
bone length that was restored by replacement of the endo-
genous c/ebpb gene with the LIP isoform (data not shown).
Histomorphometric analyses of the long bones showed that
c/ebpb/ mice have a 1.6-fold diminished bone volume,
characterized by a reduction of the number and thickness of
bone trabeculae (Figure 3A; Supplementary Table 1). In
contrast, L/L mice had a 1.7-fold increased bone volume in
comparison with WT mice, displaying increased number and
thickness of trabeculae (Figure 3A; Supplementary Table 1).
However, the number of osteoblasts was not affected in either
c/ebpb/ or in L/L mice (Supplementary Table 1). These
effects on bone tissue were observed at several sites in the
skeleton (long bones and vertebrae) (Supplementary Table 1
and data not shown). The observed bone phenotypes were
Figure 1 Expression of C/EBPb in bone cells. (A) Immuno-
histochemistry of the proximal tibia of 4-week-old mice showing
expression of C/EBPb protein (brown precipitate) in the different
bone cell types. Lightgreen was used as counterstain. Scale bar,
200mm. C/EBPb protein expression in osteoblasts (arrowheads)
(B, C), whereas no C/EBPb protein was detected in differentiated
osteoclasts (OC) (arrow), which were identified as large multi-
nucleated cells attached to the bone surface (scale bar, 50 mm) or
(C) in osteocytes (arrow, scale bar, 50mm). Tb, trabeculae; GP,
growth plate; BM, bone marrow; Cort, cortical bone (D) Western
blot analysis of C/EBPb isoform expression (LAP*, LAP and LIP)
during osteoblast differentiation (pOB, preosteoblasts; OB, osteo-
blast; mOB, mature osteoblast) and (E) during osteoclast differen-
tiation of bone marrow derived monocytic precursors on the
indicated days (d0, d3, d6) after M-CSF and RANK-L addition.
Loading was controlled by analysis of a-tubulin and a-actin expres-
sion, respectively. UD, undefined bands, which cross-react with the
C/EBPb antibody.
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Figure 2 Generation and characterization of LIP knock-in mice. (A) Schematic representation of the targeting strategy used to generate a
knock-in (k.i.) of the LIP isoform of C/EBPb in the endogenous c/ebpb locus by homologous recombination in embryonic stem (ES) cells. The
structure of the genomic c/ebpb locus, targeting vector and mutated allele are shown. The c/ebpb gene is intronless and depicted as filled red
box and LIP as dashed red box. The arrow indicates the direction of gene transcription. The DNA fragments and their sizes revealed by
Southern blot analysis are indicated by thick coloured lines. B, BamHI; N, NotI; R, R*, EcoRI; S, SalI; X, XhoI; Xa, XbaI. Neo, neomycin
resistance gene; LoxP sites (black triangles); P50: 50 probe; P30: 30 probe. (B) Southern blot analysis of ES cell DNA. Genomic DNA of targeted ES
cells was isolated from two clones and digested with EcoRI and then hybridized with the 50 probe (in purple). The WT and mutant allele are
detected as 4.5 and 3.0 kb fragments, respectively. BamHI digested DNA was hybridized with the 30 probe (in blue) that detected a 7.0-kb
fragment in the WTand a 7.8-kb fragment in the mutant allele. (C) C/EBPb protein expression in livers isolated from 8-week-old mice. Loading
was controlled by analysis of a-tubulin expression. þ /þ , WT mice; /, c/ebpb/ mice; L/L, LIP k.i. mice; þ /L, heterozygous k.i. mice.
Figure 3 Affected bone mass in c/ebpb mutant mice. (A) Histological analyses (haematoxylin-eosin staining) of tibiae of 8-week-old mice,
showing an osteopenic phenotype in c/ebpb-deficient mice (/) and an osteosclerotic phenotype in LIP k.i. mice (L/L), compared with WT
(þ /þ ) mice. Scale bar, 100 mm. Bar graph displays the histomorphometric quantification of the bone volume (BV/TV, bone volume/total
volume). GP, growth plate; Tb, trabeculae; BM, bone marrow. (B) Images of double calcein labelled bones from WTand c/ebpb mutant mice
showing the mineral apposition rate (MAR) and the bone formation rate/bone surface (BFR/BS). (C) Enhanced osteoclastogenesis in c/ebpb
mutant mice. TRACP staining of osteoclasts (red staining) in tibiae of 8-week-old WT and c/ebpb mutant mice. Lightgreen was used as
counterstain. Scale bar, 20mm. Bar graph shows the urinary excretion of deoxypyridinoline (DPD) cross-links, reflecting osteoclast activity in
vivo. For bone histomorphometric measurements, n¼ 8 per group. þ /þ , WT mice; /, c/ebpb/ mice; L/L, LIP k.i. mice. Data are
presented as mean±s.e.m. *Po0.05, **Po0.01 versus WT.
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already apparent at birth in both mutants and persisted with
age (data not shown). The increased bone volume in L/L
mice did not evoke extramedullary haematopoiesis (data not
shown). No difference in bone volume compared with WT
mice was found in c/ebpb heterozygous mice, whereas LIP
heterozygous mice displayed an intermediate phenotype
between WT and homozygous LIP mice (data not shown).
Both heterozygotes were therefore not further analysed.
The rate of bone formation was assessed in animals by
double calcein labelling. In comparison with WT, c/ebpb/
mice displayed decreased mineral apposition and bone for-
mation rate, whereas mineral apposition and bone formation
rate was increased in L/L mice (Figure 3B). Bone resorption
was enhanced in both c/ebpb/ and L/L mice as compared
with WT mice. Histomorphometric analyses revealed larger
osteoclasts (TRACP-positive cells, red staining) in both c/
ebpb/ and L/L mice, compared with WT mice (Figure 3C;
Supplementary Tables 1 and 2). Although the total number of
osteoclasts was not affected, an increase in the number of
multinucleated osteoclasts was observed (Supplementary
Tables 1 and 2). These enlarged osteoclasts caused enhanced
bone resorption, as shown by increased urinary excretion of
deoxypyridinoline (DPD) (Figure 3C). Thus, bone formation
was decreased in the absence of C/EBPb and osteoclastogen-
esis was enhanced, both contributing to the observed osteo-
penia. Expression of LIP, similarly to the absence of C/EBPb,
also enhanced osteoclastogenesis, that was however, sur-
passed by enhanced bone formation.
LIP promotes osteoblast differentiation
Osteoblasts derived from calvarial bones of L/L mice dis-
played enhanced differentiation (as also observed for long
bones derived osteoblasts, data not shown), as revealed by
increased alkaline phosphatase (ALP) activity (Figure 4A),
mineralization of bone nodules (alizarin red staining in
Figure 4B) and increased expression of early and late osteo-
blast differentiation markers, such as osteopontin, ALP, bone
sialoprotein, collagen type I and osteocalcin (OC)
(Supplementary Table 3A). Moreover, expression of the es-
sential osteogenic transcription factors Runx2 and osterix
was increased (Supplementary Table 3A), whereas no differ-
ences in the expression of several of the Wnt components
(Lef1, Tcf1 and Tcf3), or of the AP-1 family members Fra1,
Fra2, c-Fos and JunD was observed (Supplementary Table
3B). LIP has been shown earlier to act as a co-activator of
Runx2, promoting osteoblast differentiation (Hata et al,
2005), which, together with the enhanced Runx2 and
Osterix expression may contribute to enhanced osteogenesis.
These data suggest a cell autonomously enhanced differentia-
tion potential of L/L osteoblasts that may underlie the in-
crease in bone formation rate observed in L/Lmice. However,
differentiation of WT and c/ebpb/ osteoblasts in tissue
culture, either derived from calvaria or long bones (data not
shown) was similar (Figure 4A and B; Supplementary Table
3), suggesting microenvironmental cues might also be in-
volved in the observed osteopenia in c/ebpb/ mice
(Figure 3A).
Enhanced osteoclast differentiation of c/ebpb/ and
L/L cells
Osteoblasts control the differentiation and activity of osteo-
clasts by release of signalling molecules such as TNFa,
RANK-L and its antagonist OPG (Simonet et al, 1997; Boyle
et al, 2003; Teitelbaum and Ross, 2003). Analysis of both
c/ebpb/ and L/L primary osteoblasts showed diminished
expression of the pro-osteoclastogenic factors RANK-L and
TNFa and of the antagonist OPG (Figure 5A). Co-culturing
C/EBPb mutant osteoblasts with WT bone marrow cells
reduced osteoclast differentiation of WT cells (Figure 5B),
in accordance with decreased expression of osteoclastogenic
factors by the mutant osteoblasts and co-culturing WTosteo-
blasts with C/EBPb mutant bone marrow cells showed en-
hanced osteoclast differentiation of the C/EBPb mutant cells
(Figure 5C). Thus, paracrine effects do not explain the
enhanced osteoclastogenesis observed in both c/ebpb/
and L/L mice (Figure 3C) and suggest a cell autonomous
mechanism.
As shown in Figure 6A, bone marrow cell cultures from
c/ebpb/ and from L/L mice generated more and larger
osteoclasts (containing more nuclei/TRACP-positive cell)
compared with WT cells after 6 days of treatment with
M-CSF and RANK-L. Only 10% of WT osteoclasts contained
45 nuclei/cell, versus 42 and 51% in c/ebpb/ and L/L
osteoclasts, respectively (Po0.001 compared with WT). The
exacerbated osteoclast formation was accompanied by en-
hanced osteoclast activity, as shown by increased bone
resorption on bone slices (Figure 6B), increased expression
of the osteoclastic differentiation markers, TRACP, cathepsin
K (CathK), calcitonin receptor (CTR), OSCAR (osteoclast-
associated receptor) and of the osteoclastic cell fusion marker
DC-STAMP (dendritic cell-specific transmembrane protein)
(Yagi et al, 2005) (Figure 6C). Expression of RANK (RANK-
L receptor) was not affected and expression of c-Fms (M-CSF
receptor) was only slightly elevated in osteoclasts of both
mutants (data not shown), excluding elevated cytokine re-
ceptor levels as a cause of enhanced osteoclastogenesis of
mutant cells. These data are consistent with a cell intrinsic
Figure 4 Osteoblast differentiation in c/ebpb mutants. (A) Primary
calvarial osteoblast precursor cells were differentiated and stained
for alkaline phosphatase (ALP) activity. The bar graph displays
the quantification of the percentage ALP positive area per well area.
(B) Bone nodule mineralization of primary calvarial osteoblasts
determined by alizarin red staining. The bar graph displays the
quantification of alizarin red positive mineralized nodules. þ /þ ,
WT mice; /, c/ebpb/ mice; L/L, LIP k.i. mice. Data are
presented as mean±s.e.m. *Po0.05, versus WT.
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Figure 5 Osteoblast–osteoclast cross-talk in c/ebpb mutants. (A) Expression of the osteoclastic regulators RANK-L, OPG and TNFa in primary
calvarial osteoblast cultures as determined by real-time RT–PCR. Values represent relative expression levels compared with WTon day 14 (set
as 1). Data are presented as mean±s.e.m. of three independent experiments. (B) Number of multinucleated osteoclasts formed from WT bone
marrow cells (BM) co-cultured with osteoblasts (OB) from the different genotypes, as indicated. (C) Number of multinucleated osteoclasts
formed from bone marrow cells of the C/EBPb mutant mice (as indicated), co-cultured with WTosteoblasts. þ /þ , WT mice; /, c/ebpb/
mice; L/L, LIP k.i. mice. Data are presented as mean±s.e.m. *Po0.05 versus WT.
Figure 6 c/ebpb mutations promote osteoclast differentiation. (A) Osteoclast differentiation of bone marrow derived monocytic precursors
from WT, c/ebpb knock-out and LIP k.i. mice and treated with M-CSF and RANK-L. Osteoclasts were stained by TRACP activity (red staining).
The bar graph displays the differential quantification of the osteoclasts by number of nuclei per cell (WT cultures set at 100%). (B) Bone
resorptive activity of osteoclasts determined by culturing osteoclasts on bovine bone slices and staining resorption pits (arrowheads)
with coomassie brilliant blue. The bar graph displays the quantification of the resorption areas expressed as fold of resorbed area in the WT (set
at 1). (C) Real-time RT–PCR analysis of expression of the osteoclast markers TRACP, Cathepsin K (CathK), calcitonin receptor (CTR), OSCAR
and DC-STAMP in osteoclasts cultured for 6 days in the presence of M-CSF and RANK-L. Values represent relative expression levels compared
with WT (set as 1). Data are presented as mean±s.e.m.; n¼ 6 per group. *Po0.05, **Po0.01, ***Po0.001 versus WT. (D) Western blot
analysis of cleaved-caspase 3 (cl. caspase 3) expression to determine apoptosis in primary osteoclasts cultured for 6 days in the presence of
M-CSF and RANK-L. The samples were run on the same gel, but were noncontiguous, as indicated with the black lines. Loading was controlled
by a-tubulin expression. þ /þ , WT mice; /, c/ebpb/ mice; L/L, LIP k.i. mice.
C/EBPb isoforms regulate osteoclastogenesis
JJ Smink et al
&2009 European Molecular Biology Organization The EMBO Journal 5
defect of osteoclasts in C/EBPb mutants and are in accor-
dance with the observations made in animals (Figure 3C;
Supplementary Table 2).
Cultures of osteoclast precursors exhibited similar num-
bers of osteoclasts 1 day after seeding (Supplementary Figure
1A; both mononuclear and multi-nucleated TRACP-positive
cells), reflecting a comparable pool of osteoclast precursor
cells (van der Eerden et al, 2005) in all genotypes tested.
However, on day 2 of differentiation, both c/ebpb/ and L/L
bone marrow cells generated significantly more mononuclear
and multinucleated TRACP-positive cells (Supplementary
Figure 1A and B), which was accompanied by an increased
expression of the osteoclastic differentiation markers, TRACP,
CathK, CTR and OSCAR (data not shown). These data
indicate that the enhanced osteoclastogenesis of c/ebpb/
and L/L cells is initiated at early stages of osteoclast
differentiation. In agreement with this, an increase in
cleaved-caspase 3 expression was observed in C/EBPb
mutant but not in WT osteoclast cultures (Figure 6D) and
likewise, apoptotic cells were present in mutant cultures
but not in WT cultures after 6 days (data not shown).
These data signify that the presence of enlarged osteoclasts
is not caused by a diminished or delayed apoptosis of C/EBPb
mutant cells, but by accelerated differentiation and enhanced
cell fusion.
Accelerated osteoclast differentiation was accompanied by
increased expression of the osteoclastic transcription factor
NFATc1 at early stages in differentiation, whereas expression
of c-Fos was not affected (Supplementary Figure 1C). In
addition, expression of the osteoclastic cell fusion genes
ATP6v0d2 and DC-STAMP, as well as of TNFa was increased
early in osteoclast differentiation in the C/EBPb mutant
osteoclasts (Supplementary Figure 1C). TNFa has been
shown to enhance RANK-L-induced osteoclast differentiation
(Lam et al, 2000) and its contribution to the enhanced
osteoclastogenesis in c/ebpb/ and L/L cells was studied
therefore in more detail. Cell cultures from c/ebpb/ and L/L
mutant mice displayed elevated TNFa protein expression
(Supplementary Figure 2A) and neutralization of TNFa by
the TNFa antagonist Etanercept (a decoy receptor of TNFa
(Childs et al, 2001)) restrained excessive cell fusion in both
mutants (Supplementary Figure 2B). No effect of Etanercept
on the formation of osteoclasts from WT cultures was ob-
served (Supplementary Figure 2A). Thus, C/EBPb defects
augment TNFa expression, which contributes to the exacer-
bated osteoclastogenesis.
mTOR regulates osteoclastogenesis by switching
C/EBPb isoforms
Alternative translation initiation of C/EBPb isoforms can be
shifted towards LAP expression by inhibition of mTOR
signalling with rapamycin (Calkhoven et al, 2002; Jundt
et al, 2005). Bone marrow derived osteoclasts from WT or
C/EBPb mutant mice were treated with rapamycin and
stained for TRACP-activity (Figure 7A). Rapamycin comple-
tely blocked formation of multi-nucleated osteoclasts in WT
cultures (Figure 7A). In contrast, osteoclast formation was
only slightly affected by rapamycin treatment in cells from
both c/ebpb/ and L/Lmice (which do not express or cannot
switch to the LAP isoform) (Figure 7A). Protein expression
analysis confirmed that rapamycin treatment caused a shift
towards LAP expression in WT cultures (approximately five-
fold change of the LAP to LIP ratio; Figure 7B). These
data show that the inhibition of osteoclastogenesis by
rapamycin depends on C/EBPb LAP, as cells derived from
both c/ebpb/ and L/L mice are almost unresponsive. We
conclude that mTOR adjusts the expression of C/EBPb iso-
forms that in turn differentially control osteoclastogenesis.
The LAP and LIP isoforms were expressed in the RAW264.7
monocytic cell line (Figure 7D) to examine whether C/EBPb
isoforms differentially affect osteoclastogenesis. As shown in
Figure 7C, control cells transfected with EGFP differentiated
into multi-nucleated osteoclasts in the presence of RANK-L.
Ectopic expression of LIP strongly enhanced osteoclastogen-
esis. Exceptionally large osteoclasts were formed, 40% of
which contained 450 nuclei (Figure 7C). In contrast, ectopic
expression of LAP almost entirely abolished osteoclast for-
mation (Figure 7C). Most cells remained mononuclear and
TRACP-negative and only few, predominantly small TRACP-
positive osteoclasts (containing 3–5 nuclei/cell) were pre-
sent. These data show that the LAP isoform of C/EBPb
restricts osteoclastogenesis and the LIP isoform enhances
osteoclastogenesis.
C/EBPb isoforms regulate osteoclastogenesis through
MafB expression
Gene expression profiling was performed to determine pos-
sible common genetic targets of C/EBPb or rapamycin in-
volved in osteoclastogenesis. A total number of 985 genes
were differentially expressed upon LAP expression in
RAW264.7 cells under osteoclastic differentiation conditions.
Similarly, 490 genes were differentially regulated by rapamy-
cin under similar conditions. Interestingly, comparison of
LAP and rapamycin-induced gene expression profiles re-
vealed that 39% of the genes were co-regulated (of the 490
differentially expressed genes following rapamycin treatment,
189 genes were shared with the LAP-induced genes)
(Figure 8A). The extensive overlap in gene regulation further
support the notion of C/EBPb as an important target of
rapamycin in osteoclast differentiation.
Among the LAP and rapamycin activated genes, MafB
stands out (66-fold and 7.4-fold upregulated by LAP and
rapamycin treatment, respectively). MafB is a bZIP transcrip-
tion factor, recently suggested to be a negative regulator of
osteoclast differentiation (Kim et al, 2007). Rapamycin treat-
ment of WT osteoclasts increased expression of MafB
(Figure 8B) and decreased expression of various osteoclastic
markers (data not shown), confirming the profiling data. In
the C/EBPb mutant osteoclasts that are unresponsive to
rapamycin treatment and pursue unrestricted osteoclastogen-
esis, MafB expression remains low and unaffected after 2
days of culture (Figure 8B). In agreement with this, rapamy-
cin did not affect increased expression of NFATc1, ATP6v0d2
or DC-STAMP in C/EBPb mutant osteoclasts (data not
shown). In the absence of LAP (c/ebpb/ and L/L osteo-
clasts), MafB expression even further decreases during os-
teoclast differentiation compared with WTon day 6 of culture
(Figure 8C).
The MafB promoter contains a potential C/EBP binding
site (Huang et al, 2000) and LAP expression resulted in
increased MafB promoter activity, whereas LIP repressed
MafB promoter driven transactivation (Figure 8D).
Treatment of RAW264.7 cells (under osteoclastic differentia-
tion conditions) with rapamycin, similarly to LAP expression,
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resulted in transactivation of the MafB promoter (Figure 8E).
These data suggest that the LAP isoform of C/EBPb inhibits
osteoclastogenesis by increasing MafB expression and that
absence of the long C/EBPb isoforms or presence of LIP
opposes MafB expression, resulting in enhanced osteoclast
differentiation. To examine these possibilities, gene reporter
studies were carried out in C/EBPb-deficient mouse embryo-
nic fibroblasts (MEFs). In the absence of C/EBPb, the MafB
promoter could not be activated by rapamycin (Figure 8F);
however, complementation with full-length C/EBPb (WT, a
construct that contains the upstream open reading frame
(uORF)) activated the MafB promoter, which was further
enhanced by rapamycin (Figure 8F).
We conclude that rapamycin mediated mTOR inhibition
that switches C/EBPb expression towards the LAP isoform,
upregulates MafB which then in turn inhibits osteoclastogen-
esis. In support of this idea, down-regulation of MafB expres-
sion by interferring RNA overruled rapamycin treatment
whereas control small hairpin RNA (shRNA) constructs did
not affect differentiation (Figure 8G and H).
Altogether these data show that C/EBPb mediates the
inhibitory effect of rapamycin on osteoclast differentiation,
by regulating MafB. Rapamycin induces the production of the
LAP isoform of C/EBPb and LAP induces the expression of
MafB, which subsequently inhibits osteoclast differentiation
by negatively regulating osteoclastic transcription factors,
including NFATc1 (Kim et al, 2007) and its downstream
targets DC-STAMP, ATP6v0d2 and TNFa (Kim et al, 2008)
(Figure 9).
Discussion
Here, we show that isoforms of the transcription factor
CCAAT/enhancer binding protein (C/EBP) b and its alterna-
Figure 7 The mammalian target of rapamycin (mTOR) regulates osteoclastogenesis by switching C/EBPb isoforms. (A) Representative
pictures of primary bone marrow derived monocytic precursors from indicated genotypes differentiated into osteoclasts in the absence
(solvent) or presence of rapamycin. Osteoclasts were stained for TRACP after 6 days (red staining). Bar graphs show quantification of
differentiated osteoclasts (by number of nuclei per cell). The values from WT cultures was set at 100% (indicated as dashed line). Note the
difference in scale between the results from WT and mutant cultures. A representative experiment is shown. (B) Western blot analysis of
C/EBPb isoform expression (LAP*, LAP and LIP) in primary osteoclasts treated with rapamycin (Rap), as indicated. Positive control consisting
of mature osteoblasts (mOB) is shown to indicate the different C/EBPb isoforms. The positive control was run on the same gel, but was
noncontiguous, as indicated with the black line. Loading was controlled by a-tubulin expression. (C) Representative pictures of RANK-L-
induced osteoclast differentiation in RAW264.7 cells stably expressing the indicated C/EBPb isoforms or EGFP control. Osteoclasts were stained
for TRACP (red staining). Arrowheads indicate small osteoclasts present in the LAP cultures. (D) Western blot analysis of C/EBPb isoform
expression (LAP*, LAP and LIP) in RAW264.7 cells stably expressing the C/EBPb isoforms LAP or LIP, or EGFP (as control) and differentiated
into osteoclasts. The lanes were run on the same gel, but were noncontiguous as indicated with the black lines. þ /þ , WT mice; /,
c/ebpb/ mice; L/L, LIP k.i. mice.
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tive translational initiation are critical in bone formation and
resorption. We describe two complex novel bone phenotypes
in animals that either lack all C/EBPb isoforms or that
express only the truncated LIP isoform. C/EBPb-deficient
mice and mice that express the LIP isoform only (L/L) display
enhanced bone resorption. However, only C/EBPb-deficient
mice suffer from osteopenia due to combined decrease in
bone formation and enhanced resorption, whereas osteogen-
esis in LIP k.i. mutants exceeds enhanced bone resorption
and results in increased bone mass. Although resolving the
complexity of the described bone phenotypes requires further
analysis, including constructing conditional and cell-type
specific k.i. mutants, important conclusions can be drawn
from our observations.
C/EBPb and bone homeostasis
C/EBPb deficiency resulted in reduced postnatal osteogen-
esis, as suggested by recent findings obtained in prenatal and
Figure 8 C/EBPb isoforms regulate osteoclastogenesis through MafB expression (A) Venn diagram and number of differentially regulated
genes in RAW264.7 cells induced to differentiate into osteoclasts for 2 days as identified by gene array analysis. Control cells (empty vector) and
cells stably expressing LAP were compared with cells treated with rapamycin. (B) Real-time RT–PCR analysis of MafB expression in c/ebpb/
and L/L osteoclasts cultured for 2 days with M-CSF and RANK-L as well as in the absence (grey bars) or presence of rapamycin (green bars), as
indicated. Values represent relative expression levels compared with WT (set as 1). (C) Real-time RT–PCR analysis of MafB expression in
osteoclasts of WT, c/ebpb/ and L/L mice cultured for 6 days under osteoclastogenic conditions. Values represent relative expression levels
compared with WT (set as 1). Data are presented as mean±s.e.m.; n¼ 6 per group. *Po0.05, **Po0.01 versus WT. (D) Luciferase reporter
assay using a mouse MafB promoter reporter. RAW264.7 cells were transfected with empty control (EGFP) or with C/EBPb isoforms. Values
were normalized to CMV-promoter driven Renilla luciferase activity. (E) Luciferase reporter assay using a mouse MafB promoter reporter.
RAW264.7 cells were transfected with empty control (EGFP) or LAP expression vector, treated with RANK-L and with rapamycin (green bars),
as indicated. (F) C/EBPb-deficient MEFs were transfected with the mouse MafB promoter reporter and control (empty vector, EGFP) or C/EBPb
(WT) and treated with rapamycin (green bars), as indicated. Data are presented as mean±s.e.m, *Po0.05 versus control. (G) Representative
pictures of RANK-L-induced osteoclast differentiation of RAW264.7 cells with stable MafB short hairpin interfering RNA (shMafB) or control, in
the absence (solvent) or presence of rapamycin, as indicated. Osteoclasts were stained for TRACP (red staining). Bar graphs show
quantification of differentiated osteoclasts (number of nuclei per cell), in the absence (solvent) or presence of rapamycin. The values from
control cultures in the presence of solvent are set at 100%. A representative experiment is shown. (H) Knock-down of MafB using a shRNA in
RAW264.7 cells as determined by western blot analysis. The lanes were run on the same gel, but were noncontiguous. Loading was controlled
by analysis of a-tubulin expression.
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newborn mice (Tominaga et al, 2008), as well as in adult mice
(Zanotti et al, 2009). C/EBPb therefore displays non-redun-
dant functions as other C/EBP family members are
co-expressed in osteogenesis (C/EBPd and the more distantly
related CHOP (C/EBPz)) (Umayahara et al, 1999; Gutierrez
et al, 2002; Pereira et al, 2006, 2007; Shirakawa et al, 2006),
but do not rescue the phenotype of C/EBPb-deficient mice.
Tominaga and colleagues showed osteoblast differentiation
defects in c/ebpb/ osteoblasts (Tominaga et al, 2008),
whereas in our cell culture experiments, the differentiation
potential of C/EBPb-deficient osteoblasts was not affected, as
also observed when C/EBPb was downregulated in primary
osteoblasts (Zanotti et al, 2009). This discrepancy might be
related to differences in the genetic background that appar-
ently causes a more severe phenotype in C57Bl/6 as illu-
strated by the strongly reduced mendelian ratio (data not
shown) (Tominaga et al, 2008), in comparison with our
results obtained from a mixed genetic background. Thus,
the observed reduced osteogenesis in c/ebpb/ mice in vivo
may involve micro-environmental effects that impinge on
osteoblast function.
Interestingly, expression of the LIP isoform from the
murine C/EBPb locus prevents the osteopenic phenotype,
enhances osteoblast differentiation and even leads to an
osteosclerotic phenotype in the animal. Our results therefore
suggest that C/EBPb, even without its transactivation do-
main, carries out essential functions in osteogenesis. It has
been suggested that the bZIP domain of C/EBPb might serve
as a scaffold for the assembly of a transcriptionally functional
complex consisting of C/EBPb, Runx2 and ATF4, which may
enhance activation of osteogenic genes (Hata et al, 2005;
Tominaga et al, 2008). Although LIP is thought to act as a
transdominant inhibitor, it has also been suggested that long
C/EBPb isoforms could act as repressors (Kowenz-Leutz et al,
1994; Williams et al, 1995; Lamb et al, 2003; Mo et al, 2005)
and that LIP might abrogate repression by removal of long
C/EBPb isoforms (repression of a repressor) (Lamb et al,
2003). The fact that we see both, up- and downregulated
genes in C/EBPb-deficient osteoblasts, supports the notion
that C/EBPb may function as both, activator and repressor in
the same cell type and in a gene context specific manner.
However, how exactly removal of the transactivation function
of C/EBPb contributes to the enhanced gene expression in
osteoblasts will require additional experiments.
Collagen promoter based transgenic mice, which over-
express LIP in the osteoblast lineage develop osteopenia
(Harrison et al, 2005), whereas the L/L k.i. mice described
here display increased bone mass. This discrepancy could be
due to dissociation of the coupling process between LIP
expression in osteoblasts and osteoclasts, or to gene
dosage effects. The LIP-transgene might be temporally
misexpressed (Harrison et al, 2005) and the observed
osteopenia has recently been suggested to be secondary to
decreased OC expression in the bone (Tominaga et al,
2008). Moreover, in the LIP transgenic mice, all isoforms
of the endogenous C/EBPb messenger RNA are still present
and could contribute to the observed phenotype. In our study,
LIP replaces the endogenous C/EBPb gene, resulting in the
sole expression of LIP when C/EBPb becomes expressed.
Cell type and/or conditional knock-in animals will have to
be constructed to solve any remaining discrepancies and
to unravel the molecular mechanism of LIP function in
osteogenesis. Nevertheless, all data show that C/EBPb is
part of the transcription factor network regulating bone
cell functions.
C/EBPb controls osteoclastogenesis through mTOR
mediated isoform switching and MafB gene regulation
A major result of this study is the identification of C/EBPb
as regulator of osteoclastogenesis. Lack of C/EBPb, or lack of
the transactivating isoforms, resulted in the formation of
enlarged, hyperactive osteoclasts in animals and in tissue
culture. Alternative translation initiation from a single
mRNA may generate different C/EBPb isoforms. The
C/EBPb isoform ratio is adjusted by an uORF that senses
the activity status of the translation machinery, in particular
the eukaryotic translation initiation factor eIF4E, which is
controlled by the mTOR pathway. Rapamycin treatment has
been shown to inhibit osteoclastogenesis in bone marrow cell
cultures (Glantschnig et al, 2003; Kneissel et al, 2004) and to
prevent ovariectomy-induced bone loss in rats (Kneissel et al,
2004), yet the mechanism downstream of mTOR remained
unknown (Boyce et al, 2006). Our data provide the genetic
link and a rational explanation for the rapamycin effect
by showing that it depends on switching between
C/EBPb isoforms.
The phenotypic coincidence of the c/ebpb knock-out and
the L/L genotypes on one hand and the surprisingly large
overlap between genes that are activated by LAP and by
rapamycin on the other hand suggested that full-length
C/EBPb may induce expression of an osteolytic inhibitor.
Loss of an inhibitor of osteoclastogenesis as the mechanism
of C/EBPb activation is consistent with the gain-of-function
phenotype observed in both c/ebpb/ and in L/L cells.
We found that MafB was strongly upregulated by LAP and
by rapamycin and suppressed by LIP and by c/ebpb defi-
Figure 9 C/EBPb as a switch in osteoclastogenesis. Schematic
representation of how differences in mTOR activity alters the
C/EBPb isoform ratio to regulate osteoclastogenesis. Rapamycin
inhibits mTOR, which causes enhanced expression of LAP. LAP
induces expression of MafB. MafB inhibits NFATc1 and other
osteoclastic transcriptional regulators (c-Fos and Mitf), which
results in the down-regulation of osteoclastic genes including
TNFa and the cell fusion genes ATP6v0d2 and DC-STAMP (partially
derived from Kim et al, 2007, 2008). Enhanced expression of LAP
therefore inhibits osteoclast differentiation, whereas LIP (produced
at high mTOR activity) forces osteoclast differentiation.
C/EBPb isoforms regulate osteoclastogenesis
JJ Smink et al
&2009 European Molecular Biology Organization The EMBO Journal 9
ciency. MafB is a bZIP transcription factor, important for
podocyte differentiation (Sadl et al, 2002; Moriguchi et al,
2006), rhombomere specification in the early hindbrain
(Cordes and Barsh, 1994) and for respiratory control
(Blanchi et al, 2003). Moreover, in the haematopoietic
system, MafB regulates myeloid differentiation and promotes
macrophage differentiation (Sieweke et al, 1996; Kelly et al,
2000). MafB deficiency in macrophages results in an altered
actin organization (Aziz et al, 2006) and reduced F4/80
expression (Moriguchi et al, 2006). Recently, MafB has been
associated with osteoclast differentiation. MafB negatively
regulates RANK-L-induced osteoclastogenesis by attenuating
DNA binding of the key regulators NFATc1, c-Fos and Mitf
(Kim et al, 2007).
Here, we show that inhibition of osteoclastogenesis by
either expression of LAP or by rapamycin depends on MafB.
Furthermore, and as observed in c/ebpb/ and L/L osteo-
clasts, decreased levels of MafB result in increased levels of
the key regulator of osteoclastogenesis NFATc1 and its down-
stream target OSCAR (Kim et al, 2007). NFATc1 is not only a
key regulator of osteoclast differentiation (Takayanagi et al,
2002; Asagiri et al, 2005; Aliprantis et al, 2008), but also
regulates the cell fusion genes ATP6v0d2, DC-STAMP (Kim
et al, 2008) and TNFa expression (Peng et al, 2001;
Kaminuma et al, 2008). We found that in c/ebpb/ and
L/L osteoclasts the cell fusion genes ATP6v0d2, DC-STAMP
and TNFa, were upregulated. Hyperactive osteoclasts and
increased TNFa production are often involved in bone dis-
eases, including osteoporosis (Rodan and Martin, 2000;
Helfrich, 2003; Teitelbaum and Ross, 2003; Ehrlich and
Roodman, 2005). Autocrine TNFa production in osteoclasts
derived from c/ebpb/ or L/L mice indeed contributed to
augmented osteoclastogenesis, consistent with earlier reports
(Lam et al, 2000; Fuller et al, 2002; Kim et al, 2008).
Therefore, our data provide strong genetic and mechan-
istical evidence that adjustment of the C/EBPb isoform ratio
by alternative translation of C/EBPb determines the MafB
expresssion status and osteoclastogenesis (Figure 9). We
speculate that changes in C/EBPb isoform ratio could be
involved in human bone diseases and drugs targeting transla-
tional control and thus altering the C/EBPb isoform ratio may
possibly enable novel therapeutic strategies in the manage-
ment and treatment of osteolytic bone diseases, such as
osteoporosis and multiple myeloma.
Materials and methods
Generation of c/ebpb mutant mice
The c/ebpb knock-out mouse strain has been described earlier
(Sterneck et al, 1997) and the LIP knock-in mice have
been generated as described in the Supplementary data. The
genetic background of both c/ebpb knock-out and LIP knock-in
mice was 129C57Bl/6. Mice were kept under pathogen-free
conditions. Mice were bred from heterozygous breeders and
littermates were compared with each other. The WT littermates of
both c/ebpb knock-out and LIP knock-in mice displayed similar
bone parameters (bone histomorphometry and in cell culture
experiments). Therefore, the WT control group is displayed as a
single group. Animals were analysed at the age of 8 weeks. Both
female and male mice showed the same phenotype and were
analysed as one group. Mice were provided with standard mouse
diet and water ad libitum on a 12-h light–dark cycle. All procedures
and animal experiments were conducted in compliance with
protocols approved by the institutional Animal Care and Use
Committee.
Osteoclast cultures
Primary bone marrow cells from 8-week-old mice were cultured as
described earlier (de Vries et al, 2005), in the presence of 30 ng/ml
recombinant M-CSF (R&D Systems) and with or without 20 ng/ml
recombinant murine RANK-L-TEC (R&D Systems) for 6 days on
plastic or for 7 days on bovine cortical bone slices. The TNFa
antagonist Etanercept (Enbrel) was used at 10mg/ml. Rapamycin
(0.5mM) and Etanercept treatment were started at day 0. TRACP
staining was performed with the leukocyte acid phosphatase kit
(Sigma). For osteoclast cultures of 2 days, BMMs were prepared as
described before (Takayanagi et al, 2002) and osteoclast differentia-
tion was induced as described above for 2 days. To assess the
resorptive activity of osteoclasts, bone slices were stained with
coomassie brilliant blue to visualize resorption pits as described
earlier (de Vries et al, 2005). RAW264.7 cells (ATCC) were cultured
in the presence of 20 ng/ml recombinant murine RANK-L-TEC for 6
days to induce osteoclast differentiation.
Osteoblast cultures
Primary osteoblast precursors were cultured from neonatal mice
(1–6 days old) as described earlier (Jochum et al, 2000). After 14
and 21 days of culture, cells were fixed stained for ALP and
mineralized bone nodules were identified by staining with 2%
Alizarin Red S (Sigma). Co-cultures of osteoblasts and osteoclasts
were performed as described earlier (van ’t Hof, 2003).
Protein analysis
All cell types were lyzed with RIPA buffer. For osteoblasts,
proteins were isolated before adding osteoblastogenic agents
(considered as preosteoblasts), 7 days after adding osteogenic
agents (considered as osteoblasts) and at the appearance of bone
nodules (considered as mature osteoblasts). For osteoclasts,
proteins were isolated from bone marrow derived monocytic
precursors at day 0, 3 and 6 after addition of M-CSF and RANK-L.
For the liver protein extracts, 8-week-old animals were used.
Proteins were separated on 15% SDS–polyacrylamide gels, trans-
ferred onto nitrocellulose membranes and probed with anti-C/EBPb
(C-19), anti-a-tubulin or anti-a-actin (all from Santa Cruz Biotech-
nology Inc.), anti-MafB (Abcam) and anti-cleaved caspase-3 (Cell
Signaling) using standard procedures.
Biochemical assays
In vivo osteoclast activity was determined by measuring total DPD
cross-links in urine samples, which was expressed relative to
urinary creatinine levels (Metra Biosystems, Inc.). Eight animals of
each genotype were analysed.
Media samples of osteoclast cultures were collected on day 6 of
cell culture and used for quantifying TNFa protein levels by ELISA
(BD Biosciences).
RNA isolation and real-time RT–PCR
Total RNA of primary osteoclasts was isolated on day 6 of culture
using the RNeasy mini kit (Qiagen) and cDNA was synthesized
using the SuperScript II reverse transcriptase, as described by the
manufacturer (Invitrogen). Real-time RT–PCR was performed on an
ABI PRISM 7000 (Applied Biosystems) using the SYBR Green PCR
Master Mix (Applied Biosystems) as described earlier (de Vries et al,
2006). RNA of osteoblasts was isolated using TriPure isolation
reagent (Roche) and cDNA was synthesized as described for the
osteoclasts. Real-time RT–PCR analysis was performed on a
LightCycler type II (Roche) using the SYBR Green PCR Master
Mix (Roche). Expression of GAPDH was used to normalize
individual RNA expression levels. The data are expressed as relative
RNA expression levels and calculated using the comparative CT
method. The WTexpression level was set at 1. Sequences of primer
pairs used can be obtained upon request.
Expression of C/EBPb isoforms in RAW264.7 cells
The cDNAs of rat c/ebpb isoforms LAP and LIP were cloned
into a pIRES-EGFP vector. RAW264.7 cells were transfected with
FuGENE (Roche) and after 48 h, the cells were washed once and
selected for 2–3 weeks in the presence of neomycin. EGFP-positive
cells were sorted by FACS and were induced to differentiate into
osteoclasts as described above. Three independent experiments
were performed.
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Gene array analyses and shRNA experiments
For gene array analyses, total RNA was isolated from RAW264.7
control cells (empty vector) treated with rapamycin or cells
expressing LAP, using the RNeasy mini kit (Qiagen). The cells
were induced to differentiate into osteoclasts by treatment with
20ng/ml RANK-L for 48 h. RNA (1 mg) expression analysis was
performed using the Agilent 4x44K whole genome mouse array
(Agilent) and analysed per manufacturer’s instructions at ImaGenes
(Berlin, Germany). Each gene array experiment was performed in
triplicate.
For short hairpin interfering RNA experiments, shRNAs were
expressed in psiRNA (Invivogen). shRNA oligos against mouse
MafB were designed using the ‘InvivoGen’s siRNAWizard’ program
(http://www.sirnawizard.com/design.php). As control, a non-
specific shRNA was used. Sequences targeted by shRNAs: Control
(50-GTCCATCGAACTCAGTAGCT-30) and mouse MafB (50-GGCAAC
TAACGCTGCAACTCT-30). Cells were transfected with FuGENE
(Roche) and after 48 h, the cells were washed once and selected
for 2–3 weeks in the presence of zeocin. EGFP-positive cells were
sorted by FACS and were induced to differentiate into osteoclasts as
described above.
Luciferase gene reporter assay
The MafB luciferase reporter plasmid containing the –609 bp MafB
promoter inserted in the promoter-less luciferase vector pGVB2 was
a gift from M Sakai (Hokkaido University School of Medicine,
Sapporo, Japan) (Huang et al, 2000). RAW264.7 cells or sponta-
neously immortalized C/EBPb/ MEFs were transfected with
TransIT-LT1 (Mirus) with the MafB reporter plasmid, the indicated
C/EBPb expression constructs and a CMV-promoter driven Renilla
luciferase vector as an internal control at a ratio of 5:1. RANK-L or
rapamycin were added to the RAW264.7 cells and rapamycin to the
MEFs 7 h after transfection. Firefly and Renilla luciferase activity
was assayed 48h after transfection. Firefly luciferase activity was
normalized to Renilla luciferase to control for transfection
efficiency. The data are representative of three independent
experiments, duplicates are plotted as the mean±s.e.m.
Statistical analysis
In all experiments, data are expressed as means±s.e.m. and
c/ebpb/ and LIP k.i. mice were compared with WT mice.
Statistical differences between groups were determined by one-
way ANOVA with Dunnett post-test. A P-value of o0.05 was
considered to be statistically significant.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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